A method for reconstructing a three-dimensional (3D) of a sample includes displacing an outer surface of the sample at a desired sample, repeatedly activating an ultraviolet stroboscopic illuminator to produce ultraviolet excitation light at a frequency that is based on the speed of the sample, repeatedly activating a pair of laterally spaced cameras of a stereoscopic imaging unit as the outer surface of the sample is displaced to capture a plurality of 2D images of different sections of the outer surface of the sample, and reconstructing a 3D image of the sample from the plurality of 2D images of the different sections captured by the pair of cameras.
H04N 13/167 - Synchronising or controlling image signals
H04N 13/239 - Image signal generators using stereoscopic image cameras using two 2D image sensors having a relative position equal to or related to the interocular distance
H04N 13/254 - Image signal generators using stereoscopic image cameras in combination with electromagnetic radiation sources for illuminating objects
2.
RECYCLING CARBON FIBER COMPOSITES USING ELECTROMAGNETIC FIELDS
In an embodiment, the present disclosure pertains to a method of recycling that includes applying an electromagnetic field to a composite material having carbon fiber therein, heating the composition, degrading a matrix of the composite material, and recovering the carbon fiber from the composite material. In an additional embodiment, the present disclosure pertains to a method of non-contact recycling that includes applying an electromagnetic field to a composite material having carbon fiber therein with an electromagnetic applicator via at least one of direct current or alternating current, heating the composition, degrading a matrix of the composite material, and recovering the carbon fiber from the composite material. In some embodiments, the electromagnetic field is applied in a non-contact manner. In some embodiments, the heating is locally induced heating that includes increasing the temperature inside the composite material via an inside-out method thereby initiating pyrolysis within the composite material.
B29K 105/08 - Condition, form or state of moulded material containing reinforcements, fillers or inserts of continuous length, e.g. cords, rovings, mats, fabrics, strands or yarns
BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (USA)
UT- BATTELLE, LLC (USA)
Inventor
Varanasi, Venu
Aswath, Pranesh
Maginot, Megen
Lavrik, Nickolay V.
Abstract
Amorphous SiOx (SiO2), SiONx, silicon nitride (Si3N4), surface treatments are provided, on both metal (titanium) and non-metal surfaces. Amorphous silicon-film surface treatments are shown to enhance osteoblast and osteoblast progenitor cell bioactivity, including biomineral formation and osteogenic gene panel expression, as well as enhanced surface hydroxyapatite (HA) formation. A mineralized tissue interface is provided using the amorphous silicon-based surface treatments in the presence of osteoblasts and provides improved bone cell generation/repair and improved interface for secure attachment/bonding to bone. Methods for providing PEVCD-based silicon overlays onto surfaces are provided. Methods of increasing antioxidant enzyme (e.g., superoxide dismutase) expression at a treated surface for enhanced healing are also provided. Continuous generation and release of Si4+ ion into an in vitro or in vivo environment in the presence of osteoblasts/osteoblast progenitor cells, methods of employing same for enhancing the rate of bone healing/bone regeneration, is also described.
The digital human workplace solution is deployed in a customer service setting and involves a computer programmed with a digital human that is displayed to interact with the customer and adapt to inputs providing information about the user or the environment. The digital human workforce solution is also programmed to interface with one or more databases of information that can be used during the customer service interaction.
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
5.
METHOD FOR CREATING CRUDE OIL SYNTHESIZED FLUID HAVING SURFACTANT AND DEMULSIFICATION PROPERTIES
A high voltage discharge generating a plasma wave front is disposed within a headspace over an oil-containing liquid in order to create various chemical changes within the headspace, and ultimately within the liquid in order to inactivate various microbes, synthesize new chemicals, speed separation of a mixture, and aid in oil extraction. Such a discharge may be repeated at an optimum duration and duty-cycle to maximize the chemical effects of the non-equilibrium plasma at a substantially lower temperature than for an equilibrium plasma.
C10G 33/02 - De-watering or demulsification of hydrocarbon oils with electrical or magnetic means
B01J 19/00 - Chemical, physical or physico-chemical processes in general; Their relevant apparatus
B01J 19/08 - Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor
C09K 8/584 - Compositions for enhanced recovery methods for obtaining hydrocarbons, i.e. for improving the mobility of the oil, e.g. displacing fluids characterised by the use of specific surfactants
C10G 33/04 - De-watering or demulsification of hydrocarbon oils with chemical means
The digital human workplace solution is deployed in a customer service setting and involves a computer programmed with a digital human that is displayed to interact with the customer and adapt to inputs providing information about the user or the environment. The digital human workforce solution is also programmed to interface with one or more databases of information that can be used during the customer service interaction.
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
G06F 3/0487 - Interaction techniques based on graphical user interfaces [GUI] using specific features provided by the input device, e.g. functions controlled by the rotation of a mouse with dual sensing arrangements, or of the nature of the input device, e.g. tap gestures based on pressure sensed by a digitiser
A computer-implemented method for defect identification based on a defect category driven image analysis. The method includes receiving an image of a product having a manufacturing process applied to the product; categorizing the image based on an attribute of the product in the image; selecting, based on the categorizing, a subset of image processing methods; initiating application of the selected subset of image processing methods to the image; receiving output images, each from the application of one of the selected subset of image processing methods; determining scores, each for one of the subset of the image processing methods, wherein each of the scores is based on metrics associated with different image qualities of a respective one of the output images; selecting an image processing method from the subset of imaging processing methods based on the scores; and identifying a defect in the product based on the selected imaging processing method.
The present disclosure provides a vascular graft comprising i) one or more extracellular matrix compositions and ii) one or more hydrogels. In particular, the vascular grafts of the present disclosure can be functionalized and/or be completely biologic. The disclosure also provides methods of administering the vascular grafts as well as methods for forming the vascular grafts.
A61L 27/54 - Biologically active materials, e.g. therapeutic substances
A61L 33/00 - Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
9.
METHODS AND COMPOSITIONS TARGETING NUCLEUS ACCUMBENS-ASSOCIATED PROTEIN-1 FOR TREATMENT OF AUTOIMMUNE DISORDERS AND CANCERS
Provided herein are methods of for enhancing or inducing an anti-tumor response or treating an autoimmune disorder by administering a therapeutically effective amount of an inhibitor of NAC 1. Also, provided herein are methods of enhancing effectiveness of a vaccine in a subject by administering to the subject a therapeutically effective amount of an inhibitor of NAC 1. Inhibitors of NAC1 can include a chemical agent, such as a composition containing NIC3, or a biological agent that inhibit the function of NAC1 protein, such as an isolated antibody or its binding fragment thereof that binds to NAC1. Inhibitors of NAC 1 can include a biological agent that reduces the expression of NAC1 gene, such as a NAC 1-targeted siRNA administered as a nanoliposome or a CRISPR/Cas-based genome editing composition targeting the NAC1 Gene.
The present invention provides a copolymer, preferably a degradable copolymer, comprising at least first and second repeat units and/or derived from at least first, second, and third monomers.
In an embodiment, a method for measuring parameters of a liquid, where the method includes measuring pressure drops across a flow meter, measuring pressure upstream of the flow meter, and identifying at least one liquid parameter based, at least in part, on a correlation of a change in a multiphase flow parameter to pulse output. In an additional embodiment, a measuring apparatus for measuring parameters of a liquid, where the measuring apparatus includes an electronic control operable to measure pressure drops across the measuring apparatus, measure pressure upstream of the measuring apparatus, and correlate a change in a multiphase parameter to measured pulse output of the measuring apparatus.
G01F 1/10 - Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow by using mechanical effects using rotating vanes with axial admission
G01F 1/34 - Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow by using mechanical effects by measuring pressure or differential pressure
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
The present invention provides a polymer, preferably a degradable polymer, derived from monomers (A) and (B) and/or comprising a repeat unit of formula (ii) and at least one terminal group of formula (II).
Disclosed are methods and compositions for detecting glomerular disease in dogs and effectively treating dogs with glomerular diseases such as membranoproliferative immune complex-mediated glomerulonephritis (MPGN). Methods and compositions for detecting glomerular or tubular damage in cats and effectively treating cats with glomerular or tubular damage are also provided.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
An autonomous landing system includes a vertical landing aircraft, a visual cue coupled to an offshore landing platform and including a visual indicator located that extends vertically across a horizon and is maintained parallel with the horizon, and an autonomous control system configured to control a position of the aircraft with respect to the visual indicator to maneuver the aircraft into a hovering, predefined landing position above the offshore landing platform, and control the position of the aircraft with respect to the visual indicator to cause the aircraft to descend from the landing position and land on the offshore landing platform.
The present invention provides a copolymer, preferably a degradable copolymer, comprising at least first and second repeat units and/or derived from at least first, second, and third monomers.
Tumor resection is commonly practiced to prevent the progression of cancer. However, there are post-surgery concerns including the formation of a void that can allow cancer cells to escape at the surgery site, which increases the risk of metastasis. To counter this challenge, an embodiment includes a polyurethane-based shape memory foam as a tissue void-filling device that can also release anti-cancer drugs. Such foams may activate at body temperature and become malleable. Such properties may enable the foam to be shaped to precisely seal the tissue void and then serve as a drug-eluting device. Based on the drug composition with poly vinyl alcohol (PVA), the drug release profile from the foam may be altered depending on the application.
A combination micro/macro-fluidic analysis system with one or more of a droplet transition unit, a droplet cleaving unit, a droplet synchronization, and a merging unit to enable highly efficient complex droplet microfluidic assays.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
20.
SELF-SUFFICIENT LOW-COST MITIGATION MODEL TO IMPROVE RESILIENCE IN POWER UTILITY WILDFIRE RESPONSE
A method for predictive fire control, comprising identifying a plurality of wildfire risk points on a power grid, calculating a route for an unmanned aerial vehicle (UAV) to intersect with a maximum number of points as a function of a range of the UAV, controlling the UAV to traverse the route, monitoring one or more sensors for an indication of a wildfire event and controlling the UAV to release a fire retardant on the fire.
A62C 3/02 - Fire prevention, containment or extinguishing specially adapted for particular objects or places for area conflagrations, e.g. forest fires, subterranean fires
B64D 1/16 - Dropping or releasing powdered, liquid or gaseous matter, e.g. for fire-fighting
G05D 1/656 - Interaction with payloads or external entities
G05D 105/55 - for emergency activities, e.g. search and rescue, traffic accidents or fire fighting
Augmented-reality (AR) instructions for assembly of a physical object may be based on an assembly sequence divided into multiple assembly phases, using separate computational three-dimensional (3D) registration models (e.g., object recognition models) for the different phases. A user may be guided step by step through the assembly sequence, using a step counter to keep track of where in the assembly sequence the user is. In each step, an AR image may be created by rendering, overlaid onto the camera image, a virtual model of a part of the physical object to be added during the step, spatially registered with the physical object in its partially assembled state.
In an embodiment, the present disclosure pertains to a supercapacitor composed of a cathode material, a gel electrolyte, and a zinc foil anode. In some embodiments, the cathode material, the gel electrolyte, and the zinc foil anode are in a multilayered configuration. In some embodiments, the cathode and anode materials provide load-bearing capability. In an additional embodiment, the present disclosure pertains to a method of making a supercapacitor. In general, the method includes fabricating a cathode material, preparing a gel electrolyte, coating a zinc foil electrode with the gel electrolyte, and sandwiching the zinc foil electrode with the cathode material. In some embodiments, the sandwiching forms a multilayered configuration composed of the cathode material, the gel electrolyte, and the zinc foil anode.
A mechanical and electrochemical testing apparatus includes a tensile frame having a first grip and a second grip. An electrochemical cell is disposed between the first grip and the second grip. The electrochemical cell includes a working electrode port and a counter electrode port. An electrolyte is disposed in the electrochemical cell. A working electrode is coupled to the first grip and the second grip. The working electrode is in contact with the electrolyte in the working electrode port. A counter electrode is disposed in the counter electrode port. A potentiostat is coupled to the working electrode and the counter electrode.
G01N 27/27 - Association of two or more measuring systems or cells, each measuring a different parameter, where the measurement results may be either used independently, the systems or cells being physically associated, or combined to produce a value for a furthe
G01N 3/08 - Investigating strength properties of solid materials by application of mechanical stress by applying steady tensile or compressive forces
G01N 27/49 - Systems involving the determination of the current at a single specific value, or small range of values, of applied voltage for producing selective measurement of one or more particular ionic species
H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
24.
SELECTIVE DEPOSITION AND FUSION ADDITIVE MANUFACTURING METHOD WITH REDUCED BINDER CONTENT
A SDFAM method includes forming a patterned layer of metallic paste on a build structure. The metallic paste has a solvent and a binder. The method also includes removing the solvent and the binder from the metallic paste to generate a patterned layer of metallic powder. The SDFAM method also includes applying thermal energy to the patterned layer of metallic powder to fuse the patterned layer of metallic powder into a patterned layer of solid metallic build material, and repeating the forming, the removing, and the applying to form a plurality of patterned layers of solid metallic build material to create an object.
AAAR antagonist BQ123 only blocks but is not able to reverse the vasoconstriction to ET-1. In contrast, ROCK inhibitors (e.g., H-1152) effectively reverse arteriolar constriction to ET-1. Therefore, ROCK inhibition is a potent and specific choice for treating coronary ischemic diseases (abnormal vasoconstriction) associated with microvascular dysfunction with overproduced ET-1. ROCK inhibitors may also be used to treat microvascular diseases related to diabetic retinopathy and microvascular dysfunction from cancer therapy or immunosuppressive medications. Since H-1152 can also reduce the basal tone of the microvasculature, ROCK inhibitors are also good diagnostic agent(s) when used during angiogram or by noninvasive methods.
26.
COMPOSITIONS AND METHODS FOR DETECTING AND TREATMENT OF GLOMERULAR DISEASES
Disclosed are methods and compositions for detecting glomerular disease in dogs and effectively treating dogs with glomerular diseases such as amyloidosis, glomerulosclerosis, or immune complex-mediated glomerulonephritis. miRNAs associated with glomerular disease are also provided, as are kits, and methods of use.
Architectures of millimeter-wave (mm-wave) fully-integrated frequency-division duplex (FDD) transmitting-receiving (T/R) front-end (FE) modules include a duplexer (DUX), power amplifier (PA), and low noise amplifier (LNA) on a single semiconductor substrate to facilitate the development of system on a chip (SoC) for mm-wave 5th Generation (5G) wireless communications applications. The first FE module adopts a passive DUX consisting of Wilkinson power divider and ground-center-tap transformer to achieve high isolation between PA output and LNA inputs. Another FE module combines the advantages of passive DUX and power-efficient cancellation circuits to accomplish high TX-RX isolation and low noise performance at the same time. The DUX can stand alone as a single unit in a system and is used together with external PA and LNA provided in the system, or it can include its own internal PA and LNA to form a DUX FE module.
A method of characterizing brain activity includes receiving an electroencephalogram (EEG) output. In addition, the method includes determining a mathematical model of a brain using the EEG output, wherein the mathematical model comprises a plurality of ordinary differential equations (ODEs) that are determined based on the EEG output. Further, the method includes characterizing brain activity of a subject using the mathematical model.
A method of fabrication processing a pre-preg material includes applying electromagnetic heating to a composition including a fiber and a resin. The electromagnetic heating is conducted with at least one fringing field capacitor utilizing radio frequency (RF) alternating current (AC) and controlling cross-linking of the resin in the composition via the electromagnetic heating.
B29B 13/08 - Conditioning or physical treatment of the material to be shaped by using wave energy or particle radiation
B29B 11/16 - Making preforms characterised by structure or composition comprising fillers or reinforcements
B29C 35/08 - Heating or curing, e.g. crosslinking or vulcanising by wave energy or particle radiation
B29C 70/50 - Shaping or impregnating by compression for producing articles of indefinite length, e.g. prepregs, sheet moulding compounds [SMC] or cross moulding compounds [XMC]
C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
C08J 3/28 - Treatment by wave energy or particle radiation
C08J 5/24 - Impregnating materials with prepolymers which can be polymerised in situ, e.g. manufacture of prepregs
The present disclosure provides pharmaceutical compositions comprising a live attenuated bacterial strain of Brucella melitensis, in particular a live attenuated bacterial strain of Brucella melitensis is Brucella melitensis 16M ΔvjbR (BmΔvjbR). Methods of utilizing the live attenuated bacterial strain of Brucella melitensis for treatment of a patient are also provided, including wherein the patient is in need of treatment for cancer, an autoimmune disorder, and/or an inflammatory disorder.
Technologies for multimodal sensing include a wearable device having a flexible substrate and at least one multimodal sensor coupled to the flexible substrate. The multimodal sensor includes a photoplethysmography sensor and a bioimpedance sensor. The wearable device may include context sensors such as an accelerometer, a gyroscope, a temperature sensor, or a pressure sensor. The multimodal sensor may include an integrated pressure sensor. A processor of the wearable device is configured to receive sensor data from the photoplethysmography sensor and the bioimpedance sensor of the multimodal sensor that is indicative of a pulse curve of a user. The processor is further configured to correct the sensor data based on data received from the context sensors and to determine blood pressure data based on the corrected sensor data. The processor may be configured to store the blood pressure data or to transmit the blood pressure data to a remote computing device.
A process for continuously upgrading heavy oil to produce light hydrocarbon gases which are recycled in the process as a carrier gas used in spark-discharge hydrocarbon cracking within the process. The process also produces light hydrocarbon liquids which are used to upgrade the heavy oil. An apparatus for continuously upgrading heavy oil to produce light hydrocarbon gases which are recycled in the as a carrier gas used in spark-discharge hydrocarbon cracking within the apparatus. The apparatus also produces light hydrocarbon liquids which are used to upgrade the heavy oil.
C10G 15/12 - Cracking of hydrocarbon oils by electric means, electromagnetic or mechanical vibrations, by particle radiation or with gases superheated in electric arcs with gases superheated in an electric arc, e.g. plasma
C10G 55/04 - Treatment of hydrocarbon oils, in the absence of hydrogen, by at least one refining process and at least one cracking process plural serial stages only including at least one thermal cracking step
34.
Low-Loss Switching for Circuits, Low-Loss Switching for Nuclear Magnetic Resonance Radio Frequency Coils, Methods of Use, Methods of Making, Systems, and Devices
The present provides for a stimuli-responsive switches, circuits including a stimuli-responsive switch, systems include the circuit, method of switching frequencies in a nuclear magnetic resonance system, and the like. The stimuli-responsive switch can be made of a stimuli-responsive material, where a conductive material can be moved and brought in contact with disconnected conductive paths by the stimuli-responsive material so that upon stimulation a conductive path can be achieved.
G01R 33/36 - Electrical details, e.g. matching or coupling of the coil to the receiver
H01H 36/00 - Switches actuated by change of magnetic field or of electric field, e.g. by change of relative position of magnet and switch, by shielding
35.
SELECTIVE SMALL MOLECULE AGONISTS AND PARTIAL AGONISTS OF TRK RECEPTORS
The present disclosure relates to macrocyclic compounds, pharmaceutical compositions containing macrocyclic compounds, and methods of using macrocyclic compounds to treat disease, such as diseases of the eye.
C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
C07K 5/072 - Dipeptides the side chain of the first amino acid containing more carboxyl groups than amino groups, or derivatives thereof, e.g. Asp, Glu, Asn
C07K 5/083 - Tripeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
C07K 5/103 - Tetrapeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
36.
Genetically Engineered Eukaryotic Cells and Cell Lines and Uses Thereof
Provided herein are stably-modified cell lines such as HEK293 cell lines. The cell lines are modified with an insertion, such as, a transposon containing an inducible recombinase and a promoter and one of a DNA cassette encoding an excisable mitogen, a DNA cassette encoding an inducible gene of interest or a DNA cassette encoding the excisable mitogen and the inducible gene of interest. The stably-modified cell lines are used in methods for producing a biological medical product, for example, in a scalable process for producing biopharmaceuticals.
A method of forming a composition having exfoliated nanoplatelets functionalized with covalently bound surface-modifiers, includes exfoliating a layered nanoclay is exfoliated with a surfactant. The method also includes reacting the exfoliated layered nanoclay with a surface modifier comprising one or more of an epoxide, a silane, or an isocyanate.
A system for customer notification system based on outage state of risk prediction, comprising a correlator system operating on a processor and configured to receive uncorrelated outage data, weather data and graph data and to generate geographically and temporally correlated outage data, weather data and graph data. A machine learning system operating on a processor and configured to receive geographically and temporally correlated outage data, weather data and graph data and forecast data and to generate prediction data. A state of risk system operating on a processor and configured to receive the prediction data and to generate state of risk data. A customer notification system operating on a processor and configured to receive the state of risk data and to generate customer notifications as a function of the state of risk.
G06Q 10/04 - Forecasting or optimisation specially adapted for administrative or management purposes, e.g. linear programming or "cutting stock problem"
39.
DEVELOPMENT OF SPECIFICALLY TARGETED BINDERS AND ANTIMICROBIAL PEPTIDES (STAMPS) TO CONTROL CANDIDATUS LIBERIBACTER SPP.
The subject invention pertains to controlling and/or treating infections of Candidates Liberibacter spp. that leads to citrus greening in citrus plants, such as orange trees, grapefruit trees, lime trees, lemon trees and the like and potato zebra chip disease in potato and other tuber plants using specifically targeted antimicrobial peptides (STAMPs).
40.
METHOD FOR ASSESSING THE POTENCY OF CELL POPULATIONS IN REGENERATIVE MEDICINE USING BIOMARKERS
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
THE TEXAS A&M UNIVERSITY SYSTEM (USA)
Inventor
Phinney, Donald, George
Boregowda, Siddaraju, Valagerehallli
Lee, Ryang, Hwa
Abstract
TWIST1TSG6 TWIST1TSG6TWIST1TSG6TWIST1 TSG6TWIST1TSG6TSG6 therefore are biomarkers that reliably predict MSCs intrinsic differences in potency across laboratories and assay platforms. This allows one to improve donor selection in clinical trials and to tailor MSC products to specific disease indications.
G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
G16B 40/00 - ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
41.
Wearable Patch Device for Core Body Temperature Measurements
Provided herein are thermal devices and single-use temperature measurement devices to predict and to monitor core body temperature in a subject, such as a patient. The devices utilize a plurality of thermal or temperature sensors disposed on a patch and insulated one from the other and a connection to a machine learning algorithm for prediction and monitoring. Also provided are systems and methods using the thermal device or temperature monitoring device and the machine learning algorithm to predict and measure core body temperature in the subject.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The present disclosure provides methods of evaluating interactions between compositions by subjecting the interaction to Raman spectroscopy at colder temperatures. The described methods, referred to as Thermostable Raman Interaction Profiling (TRIP), provide a powerful analytical tool used for studying molecular vibrations. The methods leverage spontaneous Raman spectroscopic measurements and can be extended to other Raman spectroscopic measurements, including fast coherent anti-Stokes Raman spectroscopy (fast CARS), surface-enhanced Raman spectroscopy (SERS), stimulated Raman spectroscopy (SRS) and tip-enhanced Raman spectroscopy (TERS), to facilitate application
The subject invention pertains to controlling and/or treating infections of Candidatus Liberibacter spp. that leads to citrus greening in citrus plants, such as orange trees, grapefruit trees, lime trees, lemon trees and the like and potato zebra chip disease in potato and other tuber plants using specifically targeted antimicrobial peptides (STAMPs).
The Research Institute at Nationwide Children's Hospital (USA)
Inventor
Song, Xiaotong
Wang, Ruoning
Sarkar, Abhijit
Hu, Yue
Abstract
The present application provides methods and compositions for treating cancers using a CAR T cell therapy platform. Also provided are methods and use of the CAR T cells for treating diseases and conditions, such as cancer, and in particular any disease or condition associated with elevated adenosine or other associate marker.
The present disclosure provides a water filtration system that meets the need for production of clean, potable water. In particular, described herein is a system comprising a Pressure Energy Transformer (PET), a Contactless Reverse Osmosis (CRO) pump, and an intelligent microcontroller-based system that provides contactless energy transfer for the production of clean drinking water.
A method of preparing a nanoparticle-active pharmaceutical ingredient adduct comprising contacting a nanoparticle with a solvent under conditions suitable for the formation of a solubilized nanoparticle; contacting the solvent- nanoparticle mixturewith an active pharmaceutical ingredient under conditions suitable for forming a solubilized nanoparticle-active pharmaceutical ingredient adduct; contacting the solubilized nanoparticle-active pharmaceutical ingredient adduct with an adduct stabilizing agent to form a stabilized nanoparticle-active pharmaceutical ingredient adduct; and; recovering the stabilized nanoparticle-active pharmaceutical ingredient adduct.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
A61K 47/42 - Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
C07K 7/64 - Cyclic peptides containing only normal peptide links
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
47.
SYSTEMS AND METHODS FOR MODELING VEINS AND ASSOCIATED BLOOD VESSEL COMPONENTS
A microfluidic chip for modelling flow through a vein includes a body including a microchannel extending between a fluid inlet and a fluid outlet, wherein at least a portion of the microchannel is coated with endothelial cells that form vascular lumen, and a venous valve formed in the body and positioned along the microchannel, wherein the venous valve includes a pair of leaflets defining a pair of cusps of the venous valve, and a flow channel positioned between the leaflets.
Coated magnetic nanoparticles and methods for attracting, isolating, and/or removing of particulate waste from environments are provided. A coated magnetic nanoparticle may include an iron-containing core surrounded by a hydrophobic or amphiphilic coating. This coating can include a functional group based on PDMS such as C-PDMS, PDMS-co-APMS, and/or PDMS-OH block copolymers. The magnetic nanoparticles may be synthesized in air or air-free in an inert gas. The magnetic nanoparticles may be introduced into, for example, an aqueous environment to bind with waste contained therein through an adsorption process. The magnetic nanoparticles and bound waste may be attracted and removed from the environment by introducing an external magnetic field.
B01J 20/02 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
B01J 20/28 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
In an embodiment, the present disclosure pertains to a medical device. In some embodiments, the medical device includes a first compartmentalized microfluidic channel flanked by two microchannels and a second compartmentalized microfluidic channel. In some embodiments, the first and second compartmentalized microfluidic channels are situated vertically one to another. In some embodiments, the medical device further includes a porous membrane situated between the first and second compartmentalized microfluidic channels. In another embodiment, the present disclosure pertains to an organ-on-chip. In some embodiments, the organ-on-chip includes a top portion having three parallel microchannels. In some embodiments, the three parallel microchannels are separated by micropillars. In some embodiments, the organ-on-chip further includes a bottom portion having a fourth microchannel and a membrane between the top portion and the bottom portion.
The present disclosure relates to a synthetic estrogen receptor alpha peptide, compositions, and methods thereof for the use of enhancing insulin sensitivity and treating and/or preventing diabetes.
A method for establishing a directional wireless communication network includes establishing in an outdoor environment a connection between a first electronic device and a second electronic device along a wireless, directional line-of-sight (LoS) path extending between the first electronic device and the second electronic device, discovering a wireless, directional non-line-of-sight (NLoS) path between the first electronic device and the second electronic device, and establishing in the outdoor environment a connection between the first electronic device and the second electronic device along the NLoS path in response to the occurrence of a blockage along the LOS path.
H01Q 3/26 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the distribution of energy across a radiating aperture
Embodiments of the invention are directed to inhibitors of FabK activity. Embodiments of the inventions are directed to compounds having a structure selected from the group consisting of an imidazole scaffold, a thiazole scaffold, a pyridine-thiazole scaffold, a benzothiazole scaffold, a benzimidazole scaffold, a benzoxazole scaffold and combinations thereof.
A61K 31/417 - Imidazole-alkylamines, e.g. histamine, phentolamine
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
C07D 277/20 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
Methods and compositions for the immunization of animals and humans using an immunization or vaccine that comprises B. anthracis Sterne strain 34F2 spores suspended in alginate in an amount sufficient to protect an animal or human from a lethal dose of anthrax.
Provided herein are methods and processes for wet-towing and installing a bucket foundation or mono-bucket for a wind turbine with or without the wind turbine mounted thereto in a body of water, such as a sea, an ocean or a lake. The methods and processes utilize at least a pair of wrap buoys secured to the bucket foundation or mono-bucket where the release thereof alters buoyancy such that the bucket foundation or mono-bucket submerges to a target site in the body of water.
Methods and compositions are provided for preventing or reducing symptoms or disease associated with Xylella fastidiosa or Xanthomonas axonopodis in a plant. The invention provides novel bacteriophages virulent to Xylella fastidiosa or Xanthomonas axonopodis, including XfaMija and XfaMijo, and further provides methods for treating or preventing Pierce's Disease or Citrus Canker in plants.
C12N 1/00 - Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
Board of Regents, The University of Texas System (USA)
US Army Research Laboratory (USA)
US Hybrid Corporation (USA)
Inventor
Toliyat, Hamid A.
Praslicka, Bryton
Zamarron, Daniel
Gardner, Matthew C.
Johnson, Matthew C.
Goodarzi, Abas
Bauk, Enzo
Nguyen, Alex
Hasanpour, Shima
Duan, Godwin Yuan
Richardson, Salek Khan
Abstract
Aspects of the disclosure relate to a cycloidal magnetic gear. The cycloidal magnetic gear includes an outer rotor. A plurality of magnetic pole pairs is disposed on an inner circumference of the outer rotor. A first, second, and third inner rotor is disposed within the outer rotor. The first, second, and third inner rotors includes a magnetic pole pairs disposed on an outer circumference thereof. The first inner rotor and the third inner rotor have a thickness of approximately half the thickness of the second inner rotor. The first inner rotor, the second inner rotor, and the third inner rotor balance moments acting on a drive shaft.
H02K 51/00 - Dynamo-electric gears, i.e. dynamo-electric means for transmitting mechanical power from a driving shaft to a driven shaft and comprising structurally interrelated motor and generator parts
H02K 16/00 - Machines with more than one rotor or stator
Described herein are coating compositions and methods of treating fruits and vegetables to resemble the visual appearance of a natural wax bloom on the surface of the fruit or vegetable. The coating composition including a coating agent. The method including applying a coating composition to a surface of the fruit or vegetable, and drying the coating composition on the surface of the fruit or vegetable.
In an embodiment, the present disclosure relates to a method of restoring cytochrome c oxidase (CcO) activity in a subject in need thereof. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog thereof and rescuing defects of cells in the subject with deficiencies or mutations in at least one of SOD1, AT-1, APIS1, COA6, SCO2, COX6B1, CTR1, ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, and CLCN7. In a further embodiment, the present disclosure relates to a method of treating disorders of copper metabolism. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog to a subject, where the disorder is caused by a deficiency or mutation to a gene including, without limitation, SOD1, AT-1, APIS1, COA6, SCO2, COX6B1, CTR1, ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, CLCN7, or combinations thereof.
Processes for fabricating zinc-ion and zinc-sulfur energy storage devices are disclosed. In some aspects, a rechargeable, multifunctional quasi-solid-state zinc-sulfur battery includes sulfur-added carbon substrates, with particulate and porous carbon nanofibers as the cathode material and an anti-freezing hydrogel electrolyte coating. In some aspects, a flexible energy storage device comprises zinc-ion hybrid MEMS supercapacitors, with high areal energy density and remarkable flexibility that allows them to bend without compromising structural integrity.
The present disclosure provides method of processing neural cells comprising extracting one or more brain components from an animal, dissociating cells from the brain components to form a brain cell composition, purifying the neural cells from the brain cell composition, and culturing the neural cells. Further, the present disclosure provides in vitro assays and related kits utilizing the neural cells, for example in use to screen compounds or therapeutics for neurological diseases or disorders.
An example electrode fabricated using a solvent-free process is provided. The electrode includes a substrate including a dry mixture of active materials, binder, and conductive additives electrostatically sprayed onto the substrate, thermally activated, and bonded to the substrate. The binder and the conductive additives form conductive binder agglomeration clusters. The binder and the conductive additives uniformly cover a surface of the active materials. The binder is uniformly distributed in a thickness direction of the electrode. The electrode includes pores between the active materials that are both microsize pores and submicron- size pores. The micro-size pores are open pores that allow electrolyte to diffuse.
A highly scalable process has been developed for stabilizing large quantities of the zeta-polymorph of V2O5, a metastable kinetically trapped phase, with high compositional and phase purity. The process utilizes a beta-Cux V2O5 precursor which is synthetized from solution using all-soluble precursors. The copper can be leached from this structure by a room temperature post-synthetic route to stabilize an empty tunnel framework entirely devoid of intercalating cations. The metastable ζ-V2O5 thus stabilized can be used as a monovalent-(Li, Na) or multivalent-(Mg, Ca, Al) ion battery cathode material.
H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
A method of treating a Down syndrome (DS) subject with functional or at risk of decline of organ systems associated with accelerated aging due to over-production of H2S is disclosed. That method contemplates administering a pharmaceutical composition containing a H2S-reducing effective amount of hydrophilic polymer-substituted oxidized carbon nanoparticles (OCNPs) and an optional potentiating amount of lipoic acid or dihydrolipoic acid dissolved or dispersed in a physiologically acceptable diluent to the subject. The pharmaceutical composition can be administered parenterally as a liquid or per os as a solid or liquid.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 43/00 - Drugs for specific purposes, not provided for in groups
64.
NON-EQUILIBRIUM PLASMA-ENHANCED PRECIPITATION OF STABLE METALS, METAL SALTS AND METAL COMPLEXES FROM WASTE DISCHARGES
The invention is directed to a method of plasma-enhanced precipitation of stable metals, metal salts and metal complexes from a water source, where a sample is subjected to plasma treatment which results in the precipitation of critical minerals and materials.
In some examples, a system includes a communication network having a cloud portion and an edge portion. The communication network comprises a cloud controller, a radio access network (RAN), and an edge computing device. The edge computing device is co-located with at least a portion of the RAN. The edge computing device is configured to, within one transmission time interval (TTI) of the RAN, obtain network state information of the communication network, determine control actions for modifying operational settings of the RAN, and transmit the control actions to the RAN.
H04W 28/18 - Negotiating wireless communication parameters
H04L 41/16 - Arrangements for maintenance, administration or management of data switching networks, e.g. of packet switching networks using machine learning or artificial intelligence
An embodiment includes a system comprising: an outer conduit; a shape memory polymer (SMP) foam; a metal backbone including: (a)(i) a first portion that extends from the SMP foam proximal end to the SMP foam distal end and which is generally covered by the SMP foam, and (a)(ii) a distal portion that extends distally from the SMP foam distal end and which is not covered by the SMP foam; wherein: (b)(i) SMP foam and the metal backbone are both included within the outer conduit adjacent to the outer conduit distal end; (b)(ii) the metal backbone distal portion transitions from a secondary shape that is uncoiled to a primary shape that is coiled; and (b)(iii) the metal backbone distal portion is in the metal backbone distal portion secondary shape and is located between the SMP foam distal end and the distal end of the outer conduit.
A61B 17/12 - Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
A61B 17/00 - Surgical instruments, devices or methods, e.g. tourniquets
67.
AQUEOUS METAL BATTERIES WITH POLYANILINE-CONTAINING CATHODES
An embodiment of the invention is directed to a battery comprising: an anode; a carbon cathode with a polyaniline (PANI) deposition; and an aqueous electrolyte solution. An embodiment of the invention is directed to Fe-ion batteries comprising carbon nanotube cathodes having a PANI deposition and Fe metal anodes. Another embodiment of the invention is directed to Zn-ion batteries comprising carbon nanotube cathodes having a PANI deposition and Zn metal anodes.
Provided herein are methods and compositions for treating bacterial infections in a subject comprising providing to the subject an effective amount of a P2Y1 inhibitor, a PPK1 or PPK2 inhibitor, and/or an IP6K inhibitor.
In an embodiment, the present disclosure pertains to a composition having a cation and an anion. In some embodiments, a base is incorporated into the anion, and the cation and the anion form a bifunctional catalyst. In some embodiments, the cation is a chiral cobalt(III) species, and a nitrogenous Brpnsted base is incorporated into counter anions of the chiral cobalt(III) species cation. In some embodiments, the bifunctional catalyst is a tricationic cobalt(III) hydrogen bond donor catalyst, and a nitrogenous Brpnsted base is incorporated into counter anions of the tricationic cobalt(III) hydrogen bond donor catalyst. In another aspect, the present disclosure pertains to a bifunctional catalyst having a smart anion with a cationic metal species. In some embodiments, the smart anion performs a specific role in a chemical reaction without the inclusion of additional external components to accomplish a same specific role in the chemical reaction.
The present disclosure provides systems and methods for the benefit of surgical procedures in such austere locations. As described herein, the technology is applicable anywhere in the world where access to medical care is limited or not available but necessary, especially more than one hour away by transport. These applications include space, military field medicine, recreational wilderness medicine, sites of disasters (e.g., earthquakes, tsunamis, building collapses, etc.), healthcare in rural or underdeveloped locations, and hospitals or clinics with resource shortages or limitations.
The present disclosure provides pharmaceutical formulations comprising i) a support frame, ii) one or more bioadhesive materials, iii) a first active ingredient, and iv) a second active ingredient. The disclosure also provides methods of treating a subject using the pharmaceutical formulations for various disease states and processes for making the pharmaceutical formulation.
An apparatus for reforming hydrocarbons includes a reaction chamber including a hydrocarbon inlet, a plurality of plasma gaps, each plasma gap defined by a high voltage electrode and first and second ground electrodes, and a product outlet. The reaction chamber may have a first head space about a first plasma gap located proximal to the hydrocarbon inlet and a second head space surrounding a last plasma gap located proximal to the product outlet, with the second head space larger than the first head space. A flow rate and/or pulse frequency can be determined to obtain a desired product at an acceptable efficiency with limited or negligible production of undesired products. A reaction system can comprise multiple reaction modules connected in parallel and/or in series, with conduits between reaction modules. One or more (or all) conduits may include gas off-leaks. Each reaction module may include a reaction chamber with increasing headspace.
C01B 3/02 - Production of hydrogen or of gaseous mixtures containing hydrogen
C01B 3/38 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts
B01J 8/02 - Chemical or physical processes in general, conducted in the presence of fluids and solid particles; Apparatus for such processes with stationary particles, e.g. in fixed beds
73.
OCCIDIOFUNGIN ANALOGS AND METHODS OF MAKING AND USING
The subject invention pertains to methods of synthesizing occidiofungin analogs using a variant of occidiofungin which contains an aspartic acid (ASP7) or glutamic acid at position 7 (GLU7) instead of the previously characterized asparagine at position 7. Selective semi- synthetic analogs produced using the ASP7 and GLU7 variants displayed improved antifungal activity compared to ASN7 occidiofungin variants. The ASP7 and GLU7 variants of occidiofungin and compositions thereof can be used for treating fungal and parasitic infections as well as cancer.
C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
A thromboembolic event detection and imaging device may include an inferior vena cava sensing filter, signal circuitry, a processing unit, and a power source. Also, a method of monitoring for a thromboembolic event may include providing a thromboembolic event detection and imaging device, which may include an inferior vena cava sensing filter, signal circuitry, a processing unit, and a power source. The method may also include placing the inferior vena cava sensing filter within an inferior vena cava of a patient.
A method for determining constitutive parameters of a subject material includes collecting a force sensor output from a force sensor unit for measuring reactive forces applied to a deformation tool from a subject material travelling in a predefined direction relative to the deformation tool, collecting an image sequence output from a camera unit depicting a deformation zone formed between the deformation tool and the subject material as the subject material is plastically deformed by the deformation tool, and estimating a constitutive parameter of the subject material based on the force sensor output and the image sequence output.
Described herein are composites, including metal-metal composites and liquid-solid composites, that exhibit improved properties. Also provided are methods of making and using these composites.
Applicants have developed novel methods and compositions for controlling, treating, preventing, or ameliorating arthropod infection and identifying kinin receptor agonists and antagonists. Novel compositions include one or more active agents of small molecules antagonists or agonists of arthropod kinin receptor. Methods of preventing disease development and infestation by arthropods are disclosed as well as methods of making, using, and producing such compositions.
A01N 25/00 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
A01N 35/10 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical at least one of the bonds to hetero atoms is to nitrogen containing a carbon-to-nitrogen double bond
A01N 37/22 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N, e.g. carboxylic acid amides or imides; Thio-analogues thereof the nitrogen atom being directly attached to an aromatic ring system, e.g. anilides
A01N 43/42 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
A01N 43/52 - 1,3-Diazoles; Hydrogenated 1,3-diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A01N 43/707 - 1,2,3- or 1,2,4-Triazines; Hydrogenated 1,2,3- or 1,2,4-triazines
A01N 43/713 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with four or more nitrogen atoms as the only ring hetero atoms
A01N 43/82 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with three hetero atoms
A01N 43/84 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms six-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,4
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
A01N 47/48 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —S—C≡N groups
A01N 51/00 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds having the sequences of atoms O—N—S, X—O—S, N—N—S, O—N—N or O-halogen, regardless of the number of bonds each atom has and with no atom of these sequenc
A wearable multi-sensor device for measuring physiological properties includes a plurality of non-invasive sensors, such as a single-sided electrocardiography sensor, a bioimpedance and electrodermal activity sensor, a skin temperature sensor, and a photoplethysmography sensor. The device is configured to secure a skin-facing side of the sensors to exposed skin of a user and includes a communication module configured to receive signals from the plurality of non-invasive sensors and output data from the device, the being suitable for use in predicting glycemic events in the user.
A61B 5/0295 - Measuring blood flow using plethysmography, i.e. measuring the variations in the volume of a body part as modified by the circulation of blood therethrough, e.g. impedance plethysmography
An embodiment includes a wound dressing comprising: a shape memory polymer (SMP) foam, including open cells, having first and second states; and a hydrogel (HG) included within the cells; wherein (a) in a first position a composite, including the SMP foam and the HG, is configured to be located proximate a hemorrhagic tissue with the SMP foam in the first state; (b) in a second position the composite is configured to be expanded to the second state against the hemorrhagic tissue when the SMP foam is plasticized at 37° C. depressing a glass transition temperature (Tg) of the SMP foam to below 25° C. Other embodiments are described herein.
A61L 15/18 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
A method of producing a high molecular weight esterified lignin comprising contacting a lignin composition obtained from a renewable resource with an aqueous fluid a plurality of times to produce a washed lignin; contacting the washed lignin with an esterifying agent under conditions suitable for formation of an esterified lignin; contacting the esterified lignin with a crosslinking agent under conditions suitable for the formation of a high molecular weight esterified lignin; and recovering the high molecular weight esterified lignin. A composition comprising (i) a polymeric material and (ii) a high molecular weight esterified lignin. A carbon fiber prepared from (i) a polymeric material and (ii) a high molecular weight esterified lignin.
C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
C08K 3/011 - Crosslinking or vulcanising agents, e.g. accelerators
C08L 97/00 - Compositions of lignin-containing materials
C07C 67/08 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
81.
A PLATFORM FOR THE FAST, LABEL-FREE, AUTOMATED EVALUATION OF STERILITY AND BIOBURDEN
In an embodiment, the present disclosure pertains to a method for evaluation of sterility in a solution using impedance sensing. In another embodiment, the present disclosure pertains to a method for evaluation of bioburden in a solution. In a further embodiment, the present disclosure pertains to various devices for evaluation of sterility or bioburden.
Wearable optical devices, methods and systems for obtain dynamic and static physiological parameters from a subject are disclosed. Example devices can be worn around an appendage, such as a finger, and utilize PPG sensors to obtain signals from the appendage. The PPG sensors are positioned to acquire signals suitable to reconstruct an image of the inner appendage using, for example, diffuse optical tomography, to provide additional information. The devices, methods, and systems can obtain dynamic and static physiological parameters and accurate images in real-time.
Examples include multidimensional detecting of properties of particles, including a first measuring device measuring a property of particles, in a first domain, outputting the particles with a sequence stepped second domain modulation corresponds to first domain measurement values. The sequence steps have a step interval extending in the first domain and changing from step to step according to a trajectory. For sequence steps having a preceding step, the step's second domain modulation state differs from the preceding step. A second measuring device decodes the particles' respective first domain measurements by demodulating the sequence stepped second domain modulation, and measures a second property of the particles, over a measuring interval in the first domain from an interval start point to an interval end point. The interval start point and the interval end point are synchronized to the step start and to the step stop.
Pharmaceutical compositions comprising poorly water-soluble drugs (PSDs) and sucrose acetate isobutyrate (SAIB). The compositions are amorphous solid solutions or amorphous solid dispersions where the PSDs are present in the molecular or the amorphous state in the SAIB. The PSDs in amorphous form in the amorphous solid solutions can be stable against crystallization on exposure to elevated temperature and humidity conditions. Oral dosage forms containing the compositions are characterized by a higher dissolution rate in water, a higher serum maximum concentration (Cmax), and/or a greater area under the curve (AUG) than an equivalent oral dosage form without the SAIB.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A system for measurement of light scattering from a test article includes a light emitting device, configured to emit a light beam onto the test article along light axis, a collection assembly configured to collect scattered light from the test article along a measurement axis that is oriented at a non-zero angle from the light axis, wherein the collection assembly includes a first angular spectral filter, and a second angular spectral filter spaced from the first angular spectral filter along the measurement axis, wherein a position or orientation of at least one of the first angular spectral filter and the second angular spectral is adjustable relative to the measurement axis.
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (USA)
THE TEXAS A&M UNIVERSITY SYSTEM (USA)
Inventor
Menon, Ramkumar
Richards, Lauren
Kammala, Ananth, Kumar
Radnaa, Enkhtuya
Han, Aum
Abstract
Provided herein are devices and methods for mimicking the anatomy and physiology of a pregnancy comprising: a body defining a central cavity, inlet and outlet apertures in fluid communication with the central cavity of the body, wherein the central cavity comprises decidual cells; a first plurality of chambers in fluid communication with the central cavity, wherein the first plurality of fetal chambers comprise cells of fetal origin; a second plurality of chambers in fluid communication with the central cavity opposite the first plurality of chambers, wherein the first plurality of fetal chambers comprise cells of maternal origin; a third chamber in fluid communication with the central cavity, wherein the first plurality of fetal chambers comprise cells of the myometrium; wherein the integration of inputs and outputs from the central chamber, the first, second, and third pluralities of chambers mimics the anatomy and physiology of a pregnancy.
A61B 10/00 - Other methods or instruments for diagnosis, e.g. for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
87.
INERT GAS ENABLED EXTREME WEAR RESISTANCE OF ELECTRIFIED MOVING COMPONENTS
Hermetic sealing or encapsulation of critical components in an electromechanical system, rubbing surfaces, and the like allows for an extreme reduction in wear of moving components. For example, most of the transmission or gears of conventional or electric vehicles operate in a box or housing as in gear boxes. Adaptations may be made directly to these boxes so as to allow for inert gas-enabled reduction of wear on moving, electrified components contained within the boxes. Such boxes can be purged of air and then back-filled with dry nitrogen and/or other inert gases to prevent oxidation or oxidative/abrasive wear of rubbing substances. The concept can be adopted in stationary machinery as well, and the size of the inert gas tank can be made bigger in said stationary systems.
H02K 5/12 - Casings or enclosures characterised by the shape, form or construction thereof specially adapted for operating in liquid or gas
H02K 5/10 - Casings or enclosures characterised by the shape, form or construction thereof with arrangements for protection from ingress, e.g. of water or fingers
H02K 9/10 - Arrangements for cooling or ventilating by gaseous cooling medium flowing in closed circuit, a part of which is external to the machine casing
H02K 9/14 - Arrangements for cooling or ventilating wherein gaseous cooling medium circulates between the machine casing and a surrounding mantle
A breath capture and analysis system includes a breath inlet for capturing a user's breath. The breath is drawn into the system and retained for analysis. The system includes a membrane that allows volatile organic compounds contained in the breath to pass therethrough. The volatile organic compounds pass into a vacuum chamber that includes a residual gas analyzer that is configured to analyze the volatile organic compounds. The analyzed breath is then vacated from the system.
A system includes a physiological measurement device, a pressure sensor, and a controller. The physiological measurement device includes a biosensor configured to measure physiological signals upon placement in contact with a user. The pressure sensor is configured to measure a surface contact pressure applied to the user by the biosensor. The controller is in communication with the pressure sensor or the biosensor (e.g. PPG or BioZ or other) or both.
The present disclosure provides compositions comprising novel mass tags. The disclosure also provides methods utilizing mass tags, including methods of quantifying one or more individual lipids from a composition of lipids, methods of identifying a double bond position of an individual lipid, methods of identifying a biological correlation of an individual lipid, and methods of preparing a lipid derivative.
G01N 33/92 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol
C07D 213/73 - Unsubstituted amino or imino radicals
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
91.
PLANT ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF
Applicants have developed novel methods and compositions for treating, preventing or ameliorating the effects plant phytopathogen infestation in plants, including of Candidatus Liberibacter spp. the causal agents of citrus greening and potato zebrachip disease. Novel compositions include one or more active agents of aminocaproic acid, carbinoxamine maleate, chloroxylenol, chlorpropamide, cinoxacin, duartin, and cyclopentolate hydrochloride as well as their derivatives, or salt/acid forms thereof. Methods of preventing disease development and infestation by plant pathogens are disclosed as well as methods of making, using and producing such compositions.
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
A01N 31/04 - Oxygen or sulfur attached to an aliphatic side chain of a carbocyclic ring system
A01N 33/04 - Nitrogen directly attached to aliphatic or cycloaliphatic carbon atoms
A01N 37/44 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio-analogue of
A01N 43/42 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
A catheter control system may include a containment structure, a sensor coupled to the containment structure, and a plurality of actuators coupled to the containment structure. The containment structure may define a lumen configured to allow a fluid to flow therethrough, and a plurality of openings in fluid communication with the lumen. The sensor may be configured to detect a current position and/or orientation of the containment structure. Each of the actuators may be associated with at least one respective opening of the plurality of openings and configured to regulate fluid flow through the at least one respective opening.
Carbon-carbon bond forming reactions are the cornerstone of organic chemistry. A new class of ligands was developed for transition metal catalyzed cross-coupling reactions. These phosphine-urea ligands incorporate a urea subunit into the backbone of the ligand, which is designed to bind to the organometallic coupling partner and simultaneously facilitate and direct transmetalation of the nucleophile. Synthetic routes were designed and executed to synthesize phosphine-urea ligands. These ligands catalyze a wide variety of cross-coupling reactions including Suzuki, Negishi, and Buchwald-Hartwig cross-couplings. Aryl-aryl, alkyl-aryl, and alkyl-alkyl C—C cross-couplings are performed successfully with these ligands. In addition, specific chiral phosphine-urea ligands catalyze Negishi cross-couplings enantioselectively from a racemic alkylzinc nucleophile.
C07F 9/6584 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
In an embodiment, the present disclosure pertains to a nanocarrier having a shell and a core disposed within the shell. In some embodiments, the shell includes a functionalized surface. In an additional embodiment, the present disclosure pertains to a method of drug delivery. In general, the method includes administering a nanocarrier to a subject, targeting, by the nanocarrier, an area in the subject, and releasing a composition having the drug to the area. In some embodiments, the nanocarrier has a shell and a core disposed within the shell. In some embodiments, the shell includes a functionalized surface.
A graft cutting device includes a base, a cutting arm, and a plurality of fixators. The base has a cutting board section that defines a plurality of receptacles and pair of legs that each define a slot. The cutting arm is disposed between the pair of legs and is movably coupled to the base. The cutting arm includes a first arm member, a second arm member, a first blade, a second blade, and a spacer. The first blade and the second blade are disposed between the first arm member and the second arm member, and the spacer is disposed between the first blade and the second blade. The fixators are received within a respective receptacle and are configured to fix a piece of donor material to the cutting board section such that the dimensions of the piece of donor material are retained while fixed to the cutting board section.
Provided herein are systems and processes for hydrogen production and storage. The systems have three main components that are a plasma-based reformer, a membrane and separation component and a gas compressor(s) that form a continuous fluid loop. The systems also may have a storage system for hydrogen energy storage. In the process natural gas is reformed in the plasma-based reformer into a mix of hydrogen and low-molecular weight hydrocarbons, flowed into the membrane and separation component where the hydrogen is separated out of the mix and stored and the hydrocarbons are recirculated via the gas compressors to the plasma-based reformer.
C01B 3/34 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents
C01B 3/50 - Separation of hydrogen or hydrogen containing gases from gaseous mixtures, e.g. purification
B01J 19/08 - Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor
97.
Amyloid peptide scaffolds coordinate with Alzheimer's disease drugs
3 is T(Y or F), N(Y or F), S(Y or F) or Q(Y or F), wherein the amyloid peptide self-assembles into amyloid fibrils, and wherein the peptide has a total length of 11-13 amino acids.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
98.
SYSTEMS AND METHODS FOR PROVIDING TACTILE FEEDBACK TO A USER
A system for providing tactile feedback to a user includes a device comprising a touch surface to be touched by the user, one or more thermal elements distributed across the touch surface of the device and configured to heat the touch surface and thereby modulate the friction between the user's skin and the touch surface, and a controller connected to the one or more thermal elements and configured to control the operation of the one or more thermal elements to provide a plurality of predefined temperature distributions across the touch surface.
In an embodiment, the present disclosure pertains to a flame-retardant composite composed of a polymer, an intumescent flame retardant (IFR), and a metal-organic framework (MOF). In some embodiments, the MOF is a zeolitic imidazolate framework (ZIF). In some embodiments, the MOF is a bimetallic MOF. In some embodiments, the bimetallic MOF is a bimetal ZIF. In an additional embodiment, the present disclosure pertains to a flame-retardant composite composed of a polymer that can include, without limitation, polypropylene, polyethylene, high-density polyethylene, low-density polyethylene, polystyrene, polyvinyl chloride, poly(methyl methacrylate), a polyolefin, and combinations thereof, an IFR, and a ZIF.
A transcutaneous composition for treating an oxidative skin disorder of a mammal in need is disclosed containing an effective oxidative skin disorder treating amount of covalently-substituted oxidi zed activated charcoal (OACs) nanoparticles dissolved or dispersed in an aqueous composition containing a thickening agent providing a viscosity of about 1000 to about 20,000 cps, and about 5 to about 20 wt % of a skin permeation enhancer. A substituent of the substituted OAC comprises an average of about 2 to about 5 polyethylene glycol ( PEG) chains covalently linked to each OAC, or an average of about 2 to about 5 metal ion chelating groups covalently linked to each OAC, or an average of about 2 to about 5 PEG chains and an average of about 2 to about 5 metal ion chelating groups linked to each OAC. A method of treating an oxidative skin disorder of a mammal is also disclosed.
A61K 33/44 - Elemental carbon, e.g. charcoal, carbon black
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 39/06 - Free radical scavengers or antioxidants
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
